US2023029361A1PendingUtilityA1

Fagopyrum Nutraceutical Compositions

Assignee: DST PHARMA INCPriority: Mar 13, 2018Filed: Sep 12, 2022Published: Jan 26, 2023
Est. expiryMar 13, 2038(~11.6 yrs left)· nominal 20-yr term from priority
Inventors:Lu Wang
A61K 36/82A61K 45/06A61K 36/48A61K 36/288A61K 36/076A61K 36/536A61K 36/36A23V 2002/00A23L 33/105A61K 36/31A61K 31/353A61P 31/14A61K 36/28A61K 36/282A61K 36/70A61K 36/68Y02A50/30A61K 31/58A61P 1/16
75
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Fagopyrum dibotyo nutraceuticals and methods of their use are provided. The disclosed F. dibotyo nutraceuticals are useful to improve or increase liver function and to treat liver diseases, especially those caused by viral hepatitis. In some embodiments, the F. dibotyo nutraceuticals also contain supplementary botanical extracts to confer additional health benefits.

Claims

exact text as granted — not AI-modified
Claims: 
     
         1 . A method of inhibiting viral hepatitis in a subject in need thereof comprising administering to the subject an effective amount of the nutraceutical composition comprising an amount of  Fagopyrum dibotyo  extract effective to inhibit viruses that affect the liver. 
     
     
         2 . The method of  claim 1  wherein the subject in need thereof has hepatitis A virus, hepatitis B virus, or hepatitis C virus. 
     
     
         3 . The method of  claim 1  further comprising administration of a second therapeutic for viral hepatitis. 
     
     
         4 . The method of  claim 1  wherein the subject in need thereof has viral-induced late stage hepatitis. 
     
     
         5 . A method of improving or enhancing liver function in a subject in need thereof comprising administering to the subject an effective amount of the nutraceutical composition of  claim 1 . 
     
     
         6 . A method of treating liver disease in a subject in need thereof comprising administering to the subject a nutraceutical composition containing an effective amount of  Fagopyrum dibotyo  extract to improve or enhance liver function in the subject. 
     
     
         7 . The methods of  claim 6 , wherein the improvement in liver function or liver conditions are measured by any one of symptoms of ascites, serum levels of liver enzymes including ALT, AST, ALP or yGT levels, liver fibrosis, or liver cirrhosis. 
     
     
         8 . The method of  claim 6 , wherein the liver condition is hepatitis A virus infection, hepatitis B virus infection, or hepatitis C virus infection.

Join the waitlist — get patent alerts

Track US2023029361A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.